Isomorphic Labs, the AI-powered drug company spun out of Google’s DeepMind, just announced that it’s “getting ready” to begin human clinical trials of drugs designed by AI.

Alphabet’s Isomorphic Labs, spun out of DeepMind, is preparing to start human trials of AI-designed drugs after raising $600 million.

Isomorphic Labs, a subsidiary of Alphabet Inc., is close to human trials for its AI-designed medicines. Other companies are also racing to use AI in drug discovery.

A secretive, Google-backed lab is using artificial intelligence to invent new medicines for humanity's worst illnesses. But can we trust drugs designed by a mind that isn't human?

Isomorphic Labs was spun out of Google DeepMind, after the tech giant achieved one of the biggest biological breakthroughs in the last 50 years. ... For drugs that fail those trials, ...

Google's DeepMind spinoff Isomorphic Labs expects clinical trial of drugs it designed using AI to start this year, Bloomberg News reported, citing the company's CEO Demis Hassabis.

Google DeepMind's Isomorphic Labs is preparing for human trials of AI-designed drugs, marking a significant advancement in pharmaceutical innovation. President Colin Murdoch revealed the company's ...

Google DeepMind spinoff Isomorphic Labs expects testing on its first AI-designed drugs to begin this year, as tech startups race to turn algorithmic magic into actual treatments. The potential of ...

Isomorphic Labs is the secretive AI life sciences startup spun out of Google DeepMind with the goal of solving all disease with AI-powered drug discovery.

The oncology drug created by Isomorphic Labs using Google DeepMind’s AlphaFold 3 tool could be pivotal for cancer treatment.